Since 2015: Director emeritus of the Department for Cardiology, Friedrich- Schiller-University Jena, Germany.
Medical Consulting for Interventional Cardiology www.figulla.org
1997 – 2015: Elected Full Professor and Director of the Department for Cardiology, Friedrich- Schiller-University Jena, Germany
1988: Associate Professor of the Department of Cardiology, University Hospital Göttingen, Germany
1988: “Habilitation” and Faculty Member of the University Hospital Göttingen, Germany 1986 – 1988 Subspecialization for Cardiology
1980 – 1986: Residency for Internal Medicine at the University Hospital of Göttingen, Germany 1978 – 1980 Scientist at the Max-Planck-Institute for System-Physiology in Dortmund, Germany.
1977: Medical Internship at the St. Mary’s Health Center, St. Louis, USA
1976: Thesis at the Institute of Physiology at the University of Freiburg (Prof. Fleckenstein) 1971 – 1976 Medical School in Munich and Freiburg/Brsg., Germany
Honours and Awards
2012: Focus Benchmarking: One of the 10 most respected Cardiologists in Germany 2011 Sven-Effert-Price of the German Society for Cardiology
2008: BMBF – Nomination for the German Future Award 2008
2009: Co-founder of AVIDAL Vascular GmbH (Drug eluting balloons)
2006: Co-founder of Occlutech GmbH (Cardiac Occluders)
2006: Co-founder of JenaValve Technology GmbH (percutaneous heart valves)
Patents: approx. 60 patents in the field of interventional cardiology
Literature: approx. 500 papers (according to PubMed), 2 books, 28 book chapters
04/2015 – Present: Interventional Cardiologist and Head of Valvular Heart Disease Programm, Charité – Universitaetsmedizin Berlin
03/2013 – 03/2015: Head of Valvular Heart Disease and Interventions Program, Jena/ Germany
July 2012: Certified Specialist in Internal Medicine and Clinical Cardiology
2007 – 2012: Fellowship in Internal Medicine and Cardiology, University Hospital and Heart Center Jena/ Germany, Prof. HR Figulla
2005 – 2007: Department of Cardiothoracic Surgery University Heart Center Jena and Cologne, Prof. T. Wahlers
04/2005: Medical Doctor, (M.D.) University Jena/ Germany
1998 – 2005: Medical student at Friedrich Schiller University Jena/ Germany
04/2004 – 08/2004: Internship at University Hospital Bern/Switzerland Department of Cardiology, Prof. B. Meier
04/2002 – 03/2003: Research Trainee, Mount Sinai School of Medicine, N.Y., USA Department of Cardiothoracic Surgery, Prof. Dr. R. B. Griepp
09/1999: Internship at King Faisal Specialist Hospital Riyadh/Saudi Arabia, Department of Pediatric Cardiology
Scientific Work and Awards:
Research Focus: clinical and experimental studies in interventional treatment of valvular heart disease
05/2012: PhD thesis: Current and Perspective Interventional Treatment of Valvular Heart Disease. Experimental and Clinical Studies.
08/2012: Moderated Poster Award, ESC Congress
03/2012: Poster Award Valvular Heart Disease, ACC 2012
09/2011: Publication Award, Working Group Interventional Cardiology German Cardiac Society
04/2011: Rudolf-Thauer Poster- Award, German Cardiac Society
09/2009: Best of TCT 2009 Poster Award
10/2010: Innovations Award German Ministry of Research and Education
10/2008: Innovations Award German Ministry of Research and Education
10/2005: Doctoral thesis on cerebral protection by the use of deep hypothermia during circulatory arrest in large animal models
Dr. Amat-Santos is the Director of the Interventional Cardiology Department of Hospital Clínico Universitario of Valladolid (Spain). He was trained in Cardiology in the same center, in Interventional Cardiology at Quebec Heart & Lung Institute (Canada), and, in Statistics for Health Sciences in Autonoma University of Barcelona (Spain). He obtained a research contract from “Instituto de Salud Carlos III” (Madrid, Spain) during which he obtained his PhD “cum laude” and the first national prize from Lair Foundation to his Thesis focused on the percutaneous treatment of aortic stenosis.
Currently, Dr. Amat-Santos, is Associate Professor of Cardiology in the Valladolid University of Medicine and his research is centered in the percutaneous treatment of valvular heart disease and new therapeutic alternatives for heart failure, with more than 100 articles published in high impact journals of this field.